Harwood Advisory Group Lowers stake in Pfizer (PFE)

Pfizer (PFE) : Harwood Advisory Group reduced its stake in Pfizer by 29.65% during the most recent quarter end. The investment management company now holds a total of 9,772 shares of Pfizer which is valued at $319,154 after selling 4,119 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Oct 14, 2016.Pfizer makes up approximately 0.25% of Harwood Advisory Group’s portfolio.

Other Hedge Funds, Including , Sarasin Partners Llp boosted its stake in PFE in the latest quarter, The investment management firm added 1,056,438 additional shares and now holds a total of 4,227,505 shares of Pfizer which is valued at $138,070,313. Pfizer makes up approx 2.20% of Sarasin Partners Llp’s portfolio.British Columbia Investment Management Corp reduced its stake in PFE by selling 517,206 shares or 18.09% in the most recent quarter. The Hedge Fund company now holds 2,341,809 shares of PFE which is valued at $77,584,132. Pfizer makes up approx 0.79% of British Columbia Investment Management Corp’s portfolio.Bristlecone Advisors reduced its stake in PFE by selling 4,495 shares or 23.0% in the most recent quarter. The Hedge Fund company now holds 15,051 shares of PFE which is valued at $498,640. Pfizer makes up approx 0.18% of Bristlecone Advisors’s portfolio.Ronna Sue Cohen boosted its stake in PFE in the latest quarter, The investment management firm added 35 additional shares and now holds a total of 7,916 shares of Pfizer which is valued at $266,057. Pfizer makes up approx 0.20% of Ronna Sue Cohen’s portfolio.

Pfizer closed down -0.1 points or -0.31% at $32.66 with 1,55,69,339 shares getting traded on Friday. Post opening the session at $32.73, the shares hit an intraday low of $32.66 and an intraday high of $32.9 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Investors should note that on Sep 22, 2016, Pfizer announced a cash dividend of $0.3000. The company’s management has announced Nov 9, 2016 as the ex-dividend date and fixed the record date on Nov 11, 2016. The payable date has been fixed on Dec 1, 2016.

Many Wall Street Analysts have commented on Pfizer. Pfizer was Downgraded by Jefferies to ” Hold” on Oct 13, 2016.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.